Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AUTO3 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Autolus Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
AUTO3 + pembrolizumab is an investigational combination therapy comprising AUTO3, a bicistronic CAR T-cell therapy targeting both CD19 and CD22 antigens, and pembrolizumab, a monoclonal antibody checkpoint inhibitor targeting programmed cell death protein 1 (PD-1). AUTO3 is designed to reduce relapse due to single antigen loss in B-cell lymphomas, while pembrolizumab blocks PD-1, thereby enhancing T-cell mediated immune response against cancer cells. This combination has been studied in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), with early-phase trials showing promising objective and complete response rates, and a tolerable safety profile[1].
- Other names
- AUTO3 plus pembrolizumabAUTO-3 plus pembrolizumabAUTO 3 plus pembrolizumabAUTO3 CAR T-cell + Keytruda
02
Targets
CD19 (B lymphocyte antigen CD19)PDCD1 (Programmed cell death protein 1 receptor)CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on AUTO3 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AUTO3 + pembrolizumab.